Clinical evaluation of azelastin hydrochloride in the treatment of perennial allergic rhinitis.

概要

論文の詳細を見る
The incidence of allergic rhinitis has been increasing, and more drugs have been developed to treat it.A clinical trial was carried out on 173 patients with perennial allergic rhinitis to determine the efficacy and safety of azelastine hydrochloride, which inhibits neurotransmitter activity, especially leukotriene production and release and histamine release. It is as effective as disodium cromoglicate (DSCG) when administered orally in a single dose of 1mg.Sugarcoated tablets of azelastine hydrochloride were administered to patients with allergic rhinitis in a dose of 1mg twice daily, in the morning and at bedtime, for 4 weeks.1) Subjective symptoms (sneezing, nasal discharge, nasal obstruction and disturbed ADL) and subjective symptoms (volume of nasal discharge, swelling of the mucous membrane of the inferior concha, and eosinophilia in the nasal discharge) were significantly improved by both 2 and 4 weeks of treatment.2) General improvement (moderate or greater) was 31.2% after 2 weeks of treatment and 56.6% at 4 weeks.3) The stratified general improvement rating was significantly higher in patients with severe symptoms than in those with moderate symptoms.4) Side effects were observed in 6 patients, 3 of whom had drowsiness, 2 neutrophilia and 1 drug eruption. None of the side effects were serious however.Those azelastine hydrochloride appears to be a drug of high efficacy and safety in the treatment of perennial allergic rhinitis.